Abstracts tagged "Psoriatic arthritis"

Abstract Number: 206 • 2019 ACR/ARP Annual Meeting
Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study
Siegfried Wassenberg¹, Thilo Klopsch ², Anja Plenske ³, Silke Behnck-Knoblau ⁴, Jürgen Jobst ⁴, Pascal Klaus ⁴, Thomas Meng ⁴, Peter-Andreas Löschmann ⁴ and Rolf Rau ⁵, ¹Centre of Rheumatology, Ratingen, Germany, ²Internal Medicine Practice, Neubrandenburg, Germany, ³Pfizer Pharma GmbH, Berlin, Germany, ⁴Pfizer Pharma GmbH, Berlin, Berlin, Germany, ⁵Dusseldorf, Dusseldorf, Germany
Background/Purpose: Clinical trials showed that Etanercept (ETN) is highly effective in reducing clinical disease activity and often leading to remission and radiographic non-progression in patients…
Abstract Number: 838 • 2019 ACR/ARP Annual Meeting
Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?
Juliette Yedimenko¹, Yuxuan Jin ², Alexis Ogdie ³, Jessica Walsh ⁴, Jose Scher ⁵, Soumya Reddy ⁶ and M. Elaine Husni ¹, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Science, Cleveland Clinic, Cleveland, OH, ³Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, ⁶Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Patient-reported outcomes (PROs) are an important part of clinical decision making and are frequently used in combination with objective measures of disease activity and…
Abstract Number: 1171 • 2019 ACR/ARP Annual Meeting
Evidence of Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Minimal Disease Activity – Interim Analysis
Victoria Furer¹, Ari Polachek ², Liran Mendel ¹, David Levartovsky ³, Jonathan Wollman ⁴, Valerie Aloush ⁵, Ilana Kaufman ⁶, Hagit Sarbagil-Maman ⁷, Sara Borok ⁶, Mark Berman ⁶, Adi Broyde ⁶, Yael Lahat ¹, Mirna Zureik ¹, Sharon Nevo ¹, Daphna Paran ⁶, Iris Eshed ⁸ and Ori Elkayam ⁶, ¹Sourasky Medical Center, Tel-Aviv, Israel, ²Tel-Aviv Sourasky medical center, Tel Aviv, Israel, ³Sourasky medical center, Tel Aviv, Israel, ⁴Sourasky Medical Center, Herzelia, Israel, ⁵Tel Aviv Sourasky medical center, Tel Aviv, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Tel-Aviv Sourasky medical center, Qiryat-Ono, Israel, ⁸Sheba Medical Center, Tel Aviv, Israel
Background/Purpose: Subclinical inflammatory lesions detected by MRI are prevalent in hand joints of patients with cutaneous psoriasis (1). Yet, it is unknown whether these inflammatory…
Abstract Number: 1498 • 2019 ACR/ARP Annual Meeting
A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions
Tien Nguyen¹, Melvin Churchill ², Robert Levin ³, Guillermo Valenzuela ⁴, Joseph Merola ⁵, Alexis Ogdie ⁶, Ana-Maria Orbai ⁷, Jose Scher ⁸, Arthur Kavanaugh ⁹, Shital Agawane ¹⁰, Farid Kianifard ¹¹, Chauncy Rollins ¹¹ and Olivier Chambenoit ¹¹, ¹Department of Dermatology, University of California, Irvine, Irvine, CA, ²Arthritis Center of Nebraska, Lincoln, NE, ³Clinical Research of West Florida, Inc and University of South Florida, Clearwater/Tampa, FL, ⁴Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, ⁹University of California, San Diego School of Medicine, La Jolla, CA, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine…
Abstract Number: 1550 • 2019 ACR/ARP Annual Meeting
Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naïve to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors
Anthony Turkiewicz¹, Aubrey Trevelin Sprabery ², Amanda Gellett ², So Young Park ² and Arnaud Constantin ³, ¹Rheumatology Associates, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN, ³Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: While the composite ACR core data set is considered a standard for assessing disease severity and improvement in PsA, understanding the response rates of…
Abstract Number: 2444 • 2019 ACR/ARP Annual Meeting
Real-world Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Biologic Therapies
Jessica Walsh¹, Qian Cai ², Timothy Fitzgerald ³, Christopher Pericone ², Pankaj Shukla ⁴ and Soumya Chakravarty ⁵, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Mu-Sigma, Chicago, IL, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA
Background/Purpose: Though biologic therapies have demonstrated long-term response in randomized clinical trials for psoriatic arthritis (PsA), such patient populations and settings may not reflect the…
Abstract Number: 2464 • 2019 ACR/ARP Annual Meeting
Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results
Clara Pérez-Velásquez¹, Oihane Ibarguengoitia-Barrena ², David Montero-Seisdedos ², Lucía Vega-Alvarez ², Carmen García-Gómez ¹, Eva Galindez-Agirregoikoa ³, Silvia Pérez-Barrio ⁴, María Esther Ruiz-Lucea ², Ignacio Torre-Salaberri ², Ana Rosa Intxaurbe-Pellejero ², Olaia Fernandez-Berrizbeitia ¹, Juan María Blanco-Madrigal ², Eduardo Cuende-Quintana ², Itziar Calvo-Zorrilla ², Iñigo Gorostiza-Hormaeche ⁵, Natalia Andrea Rivera-García ², María Jesus Allande-López-Linares ², Helena Ugarte-Zuazo ² and María García-Vivar ¹, ¹University Hospital of Basurto, Bilbao, Pais Vasco, Spain, ²Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ³Hospital de Basurto, Bilbao, Pais Vasco, Spain, ⁴University Hospital of Basurto, Dermatology Department, Bilbao, Pais Vasco, Spain, ⁵Investigation Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain
Background/Purpose: The multidisciplinary unit of psoriatic arthritis (PsA) are attractive to improve the early diagnosis and optimize the management of complex patients with PsA. There…
Abstract Number: 2484 • 2019 ACR/ARP Annual Meeting
Gender Influence on Treatment Effectiveness in Psoriatic Arthritis
Diego Benavent¹, Chamaida Plasencia ², Victoria Navarro-Compán ³, Diana Peiteado ⁴, Alejandro Villalba ⁵, Laura Nuño ⁶, Elisa Fernández ⁷ and Alejandro Balsa ², ¹Hospital Universitario La Paz, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ³University Hospital La Paz, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, ⁵FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, ⁶Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ⁷Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain
Background/Purpose: Gender has been lately suggested as influential in the response to treatment with biological drugs in spondyloarthritis. However, data about the association between gender…
Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting
Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Luciano Fernando Lo Giudice¹, Maria Laura Acosta Felquer ¹, Luis Daniel Mazzuoccolo ², Maria Laura Galimberti ² and Enrique Soriano ³, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…
Abstract Number: 2877 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
Kim Papp¹, Melinda Gooderham ², Akimichi Morita ³, Alan Kivitz ⁴, Ranjeeta Sinvhal ⁵, Andrew Topp ⁵, Graham Heap ⁵, Ann Eldred ⁵ and Philip Mease ⁶, ¹K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, Waterloo, ON, Canada, ²2School of Medicine, Queen’s University, Kingston, ON and Skin Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada, ³Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵AbbVie Inc., North Chicago, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is characterized by peripheral synovitis, enthesitis, dactylitis and spondylitis, and IL-23 is involved in the pathogenesis of these conditions either directly…
Abstract Number: 248 • 2019 ACR/ARP Annual Meeting
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Caroline Swift ¹, Yvonne Viteri², Gail Bridges ³, Mary Dorholt ⁴ and Monal Kohli ⁵, ¹Express Scripts, St. Louis, MO, ²Accredo, Northvale, NJ, ³Accredo, Memphis, TN, ⁴Accredo, Maple Grove, MN, ⁵Express Scripts, Franklin Lakes, NJ
Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…
Abstract Number: 1003 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Improves Arterial Stiffness with Cs DMARDs-resistant Active Psoriatic Arthritis: A Cohort Extended Study
Kensuke Kume¹, kanzo amano ¹, toshikatsu kanazawa ¹, susumu yamada ¹ and kazuhiko hatta ¹, ¹Department of Rheumatology/Hiroshima Clinic, Hiroshima, Hiroshima, Japan
Background/Purpose: Background/ Patients with psoriatic arthritis (PsA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascular prevention in PsA1). But there…
Abstract Number: 1175 • 2019 ACR/ARP Annual Meeting
Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA
Xenofon Baraliakos¹, Philipp Sewerin ², Eugenio de Miguel ³, Christine Kleinmond ⁴, Ankita Shekhawat ⁵, Annette Wiedon ⁶ and Frank Behrens ⁷, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴ClinProject GmbH, Eurasburg, Germany, ⁵Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁶Novartis Pharma GmbH, Nürnberg, Germany, ⁷CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany
Background/Purpose: Enthesitis is a hallmark feature of Spondyloarthritis (SpA), and frequently localizes at the Achilles tendon1. Enthesitis is predominantly measured with clinical scores like Leeds…
Abstract Number: 1503 • 2019 ACR/ARP Annual Meeting
Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
Mark Genovese¹, Hideto Kameda ², Proton Rahman ³, Juan Cañete ⁴, Sandra Garces ⁵, Wen Xu ⁶, Matthew M. Hufford ⁵ and Bernard Combe ⁷, ¹Stanford University, Stanford, CA, ²Toho University, Tokyo, Japan, Tokyo, Japan, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that specifically targets IL-17A. Pooled safety data from IXE studies in moderate-to-severe plaque psoriasis (PsO) and psoriatic…
Abstract Number: 1553 • 2019 ACR/ARP Annual Meeting
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
Philip Mease¹, Atul Deodhar ², Renato Calheiros ³, Xiangyi Meng ³, Todd Fox ⁴ and Xenofon Baraliakos ⁵, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: AS is a chronic, inflammatory disease of the axial skeleton associated with pain, stiffness, disability, and reduced quality of life (QOL).1 AS is defined…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].